Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aspirin in immune thrombocytopenia patients with cardiovascular disease
2024-513846-13-00Phase 4Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lysine acetylsalicylate in immune thrombocytopenia (ITP), cardiac morbidity and arterial thrombosis, sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Platelet production of thromboxane B2 (TXB2) 24 hours after a 75 mg aspirin intake. Started May 2024; status: completed.
02
Drugs
lysine acetylsalicylate
03
Conditions
immune thrombocytopenia (ITP)cardiac morbidityarterial thrombosis
Beyond the preview
Go deeper on 2024-513846-13-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-513846-13-00.